Provided by Tiger Trade Technology Pte. Ltd.

Atai Beckley Inc

7.38
-0.0400-0.54%
Post-market: 7.30-0.0800-1.08%19:59 EDT
Volume:4.31M
Turnover:31.97M
Market Cap:2.73B
PE:-3.46
High:7.45
Open:7.41
Low:7.38
Close:7.42
52wk High:7.45
52wk Low:3.27
Shares:369.95M
Float Shares:294.14M
Volume Ratio:0.51
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1359
EPS(LYR):-2.9137
ROE:-417.21%
ROA:-39.03%
PB:15.48
PE(LYR):-2.53

Loading ...

U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings

Reuters
·
Mar 27

AtaiBeckley initiated with a Buy at Deutsche Bank

TIPRANKS
·
Mar 27

A Look At AtaiBeckley (ATAI) Valuation After Index Inclusions And Positive BPL-003 Phase 2a Results

Simply Wall St.
·
Mar 26

AtaiBeckley Chief Medical Officer Craig Kevin James disposes of USD 355,000 in common shares

Reuters
·
Mar 25

AtaiBeckley Joins CRSP U.S. Benchmark Indices Tracking USD 3 trillion

Reuters
·
Mar 24

Weighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility

Simply Wall St.
·
Mar 18

ATAI Life Sciences Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 18

BRIEF-Bpl-003 Demonstrates Rapid And Durable Antidepressant Effects In Treatment-Resistant Depression Phase 2A Data Published In Journal Of Psychopharmacology Phase 3 Program On Track For Q2 2026 Initiation

Reuters
·
Mar 17

Atai Beckley’s BPL-003 Phase 2a trial in treatment-resistant depression shows 12.6-point MADRS reduction by Day 2

Reuters
·
Mar 17

Atai Beckley Inc. Files Initial Beneficial Ownership Statement for CFO Michael E. Faerm

Reuters
·
Mar 14

Stock Track | Atai Beckley Inc Soars 5.01% Intraday as Depression Drug Advances to Phase 3 Trials After Successful FDA Meeting

Stock Track
·
Mar 10

BUZZ-AtaiBeckley rises as depression drug moves toward late‑stage trials

Reuters
·
Mar 10

Atai Beckley spotlights BPL-003 Phase 3 Q2 2026 start at 2026 Virtual Investor Day

Reuters
·
Mar 10

Ataibeckley Inc - Cash Runway Reaffirmed Through Planned Early-2029 Topline Phase 3 Readouts

THOMSON REUTERS
·
Mar 10

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

GlobeNewswire
·
Mar 10

Market Chatter: AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate

MT Newswires Live
·
Mar 10

Stock Track | Atai Beckley Soars 10.03% Intraday Following Positive Analyst Ratings and BPL-003 Optimism

Stock Track
·
Mar 09

BRIEF-AtaiBeckley Files For Mixed Shelf Offering

Reuters
·
Mar 09

ATAI Life Sciences Price Target Maintained With a $14.00/Share by Needham

Dow Jones
·
Mar 09

Ataibeckley: Files for Resale of up to 74.3 Mln Shares of Common Stock by the Selling Shareholder - SEC Filing

THOMSON REUTERS
·
Mar 09